Ascendis Pharma Reports Third Quarter 2024 Financial Results

23 hours ago · --Ascendis Pharma A/S today announced financial results for the third quarter ended September 30, 2024, and provided a business update. We are ready and very excited …

CouponFollow Extension

€57
OFF

Ascendis Pharma Reports Third Quarter 2024 Financial Results

2 weeks from now

23 hours ago · Ascendis Pharma reported Q3 2024 financial results with total revenue of €57.8 million, including SKYTROFA revenue of €47.2 million and YORVIPATH ex-U.S. revenue of …

stocktitan.net

€99
OFF

Ascendis Pharma Reports Third Quarter 2024 Financial Results

2 weeks from now

23 hours ago · For the third quarter of 2024, Ascendis Pharma reported a net loss of €99.2 million, or €1.72 per share (basic and diluted) compared to a net loss of €162.2 million, or €2.88 per …

businessinsider.com

€220
OFF

Ascendis Pharma Reports Second Quarter 2024 Financial Results

2 weeks from now

Sep 3, 2024 · Revising full year 2024 SKYTROFA revenue outlook to €220 -€240 million. Conference call today at 4:30 pm ET. COPENHAGEN, Denmark, Sept. 03, 2024 (GLOBE …

yahoo.com

€48
OFF

Ascendis Pharma Reports Third Quarter 2023 Financial Results

2 weeks from now

Nov 7, 2023 · Third Quarter 2023 Financial Results Total revenue for the third quarter of 2023 was €48.0 million compared to €15.3 million during the same period in 2022. The increase was …

ascendispharma.com

15%
OFF

Royalty Pharma Reports Third Quarter 2024 Results

2 weeks from now

Nov 6, 2024 · Royalty Receipts was $732 million in the third quarter of 2024, an increase of 15% compared to $637 million in the third quarter of 2023, primarily driven by strong growth from …

royaltypharma.com

€600
OFF

Ascendis Pharma Reports Third Quarter 2024 Financial Results

2 weeks from now

1 day ago · Ascendis Pharma Reports Third Quarter 2024 Financial Results November 14, 2024 at 04:02 pm EST Share ... (SG&A and R&D) to be approximately €600 million for 2024. Third …

marketscreener.com

$4
OFF

Cocrystal Pharma Reports Third Quarter 2024 Financial Results

2 weeks from now

The net loss for the third quarter of 2024 was $4.9 million, or $0.49 per share, compared with a net loss for the third quarter of 2023 of $4.2 million, or $0.41 per share, that included a $1.6 ...

nasdaq.com

$60
OFF

HOOKIPA Pharma Reports Third Quarter 2024 Financial Results …

2 weeks from now

23 hours ago · Third Quarter 2024 Financial Results Cash Position: HOOKIPA’s cash, cash equivalents and restricted cash as of September 30, 2024 was $60.0 million, compared to …

businessinsider.com

FAQs about Ascendis Pharma Reports Third Quarter 2024 Financial Results Coupon?

What happened to Ascendis Pharma A/S?

COPENHAGEN, Denmark, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the second quarter ended June 30, 2024, and provided a business update. ...

Does Ascendis Pharma (asnd) have financial results?

COPENHAGEN, Denmark Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the third quarter ended and provided business updates. ...

How many ordinary shares does Ascendis Pharma have?

As of September 30, 2024, Ascendis Pharma had 60,642,144 ordinary shares outstanding, including 881,730 ordinary shares represented by ADSs held by the company. Conference Call and Webcast Information Ascendis Pharma will host a conference call and webcast today at 4:30 pm Eastern Time (ET) to discuss its third quarter 2024 financial results. ...

How did Ascendis Pharma perform in the third quarter of 2024?

The change was primarily tied the impact of currency fluctuations. For the third quarter of 2024, Ascendis Pharma reported a net loss of €99.2 million, or €1.72 per share (basic and diluted) compared to a net loss of €162.2 million, or €2.88 per share (basic and diluted) for the same period in 2023. ...

What time does Ascendis Pharma hold a conference call & webcast?

Conference Call and Webcast Information Ascendis Pharma will host a conference call and webcast today at 4:30 pm Eastern Time (ET) to discuss its third quarter 2024 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. ...

Does Ascendis Pharma make any forward-looking statements?

Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA®, and YORVIPATH® are trademarks owned by the Ascendis Pharma group. © November 2024 Ascendis Pharma A/S. ...